GLP-1 Receptor Agonists Show Promise in Reducing Cardiovascular and Kidney Risks in Type 1 Diabetes
Adult patients with type 1 diabetes (T1D) face a greater risk of cardiorenal disease, including heart failure (HF) and chronic kidney disease (CKD), compared to those with type 2 diabetes. Despite advancements in managing blood sugar levels, a significant percentage of individuals with T1D still experience major adverse cardiovascular events (MACEs) and end-stage kidney disease (ESKD). Modern strategies are needed to prevent these events in this high-risk population.
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have demonstrated cardiovascular and kidney benefits in individuals with type 2 diabetes, obesity, and atherosclerotic cardiovascular disease. However, clinical trials evaluating these benefits have largely excluded those with T1D, and evidence in this population is limited to smaller studies focusing on surrogate outcomes like glycemic control and weight loss.
Recent research utilized a target trial emulation approach, applying principles of randomized controlled trial design to observational data from a large electronic health record database. This study evaluated the long-term effectiveness and safety of initiating GLP-1RA treatment in over 174,000 individuals with T1D.
The study, which followed patients for a median of 38 months, examined the impact of GLP-1RA initiation on MACEs (myocardial infarction, stroke, or all-cause mortality) and ESKD (dialysis or kidney transplantation). Secondary outcomes included hospitalization for heart failure, major adverse liver events, and weight loss. Safety outcomes assessed included hospitalization for diabetic ketoacidosis (DKA), severe hypoglycemia, and gastrointestinal events.
The research involved emulating 135 target trials constructed over a period of more than a decade. Individuals initiating GLP-1RA treatment were compared to a control group, with baseline characteristics carefully balanced through statistical weighting.
The findings suggest a potential benefit of GLP-1RAs in mitigating cardiovascular and kidney risks in individuals with type 1 diabetes, though further research is warranted to confirm these results. The study emphasizes the importance of addressing risk factors and diabetes complications to improve outcomes for those living with T1D.